— Know what they know.
Not Investment Advice

INIS OTC

Radnostix, Inc.
1W: +3.3% 1M: +14.6% 3M: -6.7% YTD: +5.0% 1Y: +5.0% 3Y: +37.5% 5Y: -42.7%
$0.06
-0.00 (-3.08%)
 
Weekly Expected Move ±11.4%
$0 $0 $0 $0 $0
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 58 · $33.3M mcap · 107M float · 0.041% daily turnover · Short 44% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$33.3M
52W Range0.0453-0.11
Volume17,043
Avg Volume43,467
Beta1.22
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOShahe Bagerdjian
Employees45
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date1997-08-14
4137 Commerce Circle
Idaho Falls, ID 83401
US
208 524 5300
About Radnostix, Inc.

Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.

Recent Insider Trades

NameTypeSharesPriceDate
GROSSO CHRISTOPHER G P-Purchase 0 $0.07 2026-06-26
Atcher Robert A-Award 250,000 — 2025-10-10
Laflin Steve A-Award 500,000 $0.06 2025-10-10
GROSSO CHRISTOPHER G A-Award 500,000 $0.06 2025-10-10
Bagerdjian Shahe A-Award 37,500,000 — 2025-10-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms